# EDGAR Filing Document

**Accession Number:** 0000749647
**File Stem:** 0001493152-25-011440
**Filing Date:** 2025-7
**Character Count:** 11831
**Document Hash:** 32e06a2d961cbaad9fb6550597d18b95
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-011440.hdr.sgml**: 20250728

**ACCESSION NUMBER**: 0001493152-25-011440

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250728

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250728

**DATE AS OF CHANGE**: 20250728

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Imunon, Inc.
- **CENTRAL INDEX KEY:** 0000749647
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 521256615
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15911
- **FILM NUMBER:** 251152995

**BUSINESS ADDRESS:**
- **STREET 1:** 997 LENOX DRIVE
- **STREET 2:** SUITE 100
- **CITY:** LAWRENCEVILLE
- **STATE:** NJ
- **ZIP:** 08648
- **BUSINESS PHONE:** (609) 896-9100

**MAIL ADDRESS:**
- **STREET 1:** 997 LENOX DRIVE
- **STREET 2:** SUITE 100
- **CITY:** LAWRENCEVILLE
- **STATE:** NJ
- **ZIP:** 08648

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Celsion CORP
- **DATE OF NAME CHANGE:** 20071121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CELSION CORP
- **DATE OF NAME CHANGE:** 19980515

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHEUNG LABORATORIES INC
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 28, 2025**

**Imunon, Inc.**

**(Exact name of registrant as specified in its Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-15911** | **52-1256615** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **997 Lenox Drive, Suite 100, Lawrenceville, NJ** | **08648-2311** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(609) 896-9100**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

---

| | |
|:---|:---|
| Title of each class | Name of each exchange on which registered |
| Common stock, par value $0.01 per share IMNN | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events.**

On July 28, 2025, Imunon, Inc. (the "Company"), issued a press release announcing that the Company's Board of Directors approved a 15% stock dividend, 0.15 shares of common stock (the "Stock Dividend") per share of the Company's issued and outstanding shares of common stock, par value $0.01 per share (the "Common Stock"), and per each common stock equivalent with dividend rights.

The Board of Directors has fixed August 7, 2025 as the record date (the "Record Date") for the Stock Dividend, and the Stock Dividend will be payable on August 21, 2025 to stockholders of record as of the Record Date.

The information contained in Exhibit 99.1 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| 99.1 | [Press Release, dated July 28, 2025](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **IMUNON INC.** | **IMUNON INC.** |
| Dated: July 28, 2025 | By: | */s/ Susan Eylward* |
|  |  | Susan Eylward |
|  |  | General Counsel and Corporate Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

**IMUNON Announces Stock Dividend Boosting Shareholder Value**

***Stock Dividend Reflects Company's Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders***

**LAWRENCEVILLE, N.J., July 28, 2025 (GLOBE NEWSWIRE) — <u>IMUNON</u>, Inc. (Nasdaq: IMNN)**, a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that its Board of Directors approved a 15% stock dividend, 0.15 shares of common stock per share of common stock and per each common stock equivalent with dividend rights. This stock grant reflects IMUNON's confidence in its clinical programs, long-term growth strategy, and its dedication to rewarding shareholders.

The stock dividend program will distribute a total of approximately 448,000 shares of additional shares of IMUNON common stock for each share (or common stock equivalent) held, payable to such holders of record as of August 7, 2025. The distribution is expected to occur on August 21, 2025. Stockholders will not be required to take any action to receive the dividend. After the payment date, stockholders' book entry accounts will be credited with the additional shares that represent the stock dividend. When shares are held in a brokerage account in the name of a broker, the additional shares will be distributed to the broker on the stockholder's behalf. The stock dividend is administered by Equiniti Trust Company, the Company's transfer agent.

"We are pleased to announce this stock dividend as a way to share our recent clinical progress and optimism with our shareholders," said Stacy R. Lindborg, President and CEO of IMUNON. "This action underscores our commitment to creating value while we continue to advance our innovative pipeline of therapies aimed at addressing critical unmet medical needs, including our lead IMNN-001 program in advanced ovarian cancer that recently reported unprecedented Phase 2 clinical data and is currently advancing in a Phase 3 pivotal trial."

IMUNON remains focused on its mission to develop transformative treatments, with ongoing clinical programs. The Company believes this stock dividend will further align its shareholder base with its vision for sustained growth and innovation.

**About IMUNON** 

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas<sup>®</sup>, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine<sup>®</sup>, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit **<u>www.imunon.com</u>**.

**Forward-Looking Statements** 

*IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the Company's ability to regain compliance with Nasdaq's continued listing requirements, the timing of enrollment of the Company's clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company's products, if approved, the potential efficacy and safety profile of our product candidates, and the Company's plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), and include statements regarding our planned stock split. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, risks and uncertainties related to the reverse stock split having the desired effect, our ability to regain compliance with Nasdaq's listing requirements, the potential de-listing of our shares on Nasdaq, risks and uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON's filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.* 

**Contacts:** 

---

| | |
|:---|:---|
| **Media** | **Investors** |
| Jenna Urban | Peter Vozzo |
| CG Life | ICR Healthcare |
| 212-253-8881 | 443-213-0505 |
| **<u>jurban@cglife.com</u>** | **<u>peter.vozzo@icrhealthcare.com</u>** |

---